Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson reported that TREMFYA met the primary and major secondary endpoints in the 411-patient Phase 4 STAR trial in biologic-naive psoriatic arthritis patients with MRI-confirmed axial involvement. At Week 24, guselkumab improved axial symptoms, including spinal pain and stiffness, and significantly reduced sacroiliac-joint inflammation on MRI versus placebo, with no new safety signals. The results strengthen TREMFYA's clinical evidence in an underserved PsA subgroup, though detailed efficacy data and regulatory implications have not yet been disclosed.

Analysis

This is strategically positive for JNJ's immunology franchise but unlikely to alter near-term earnings estimates: the addressable population is definitionally unstable, and topline disclosure omits effect sizes, responder thresholds, durability and discontinuation rates. The investable value is evidence differentiation: MRI-confirmed inflammation can support rheumatologist switching and formulary discussions, especially when treatment decisions increasingly require objective proof rather than patient-reported back-pain outcomes. A successful detailed readout could modestly extend TREMFYA's PsA growth runway and defend share as biosimilar and class competition intensifies.

ABBV's SKYRIZI is the clearest second-order loser because it competes in IL-23 across psoriasis/PsA and has a larger franchise whose valuation embeds continued immunology execution. However, STAR does not establish class superiority; it may instead validate IL-23 as a credible axial-PsA category, creating a read-through benefit for ABBV if payers and physicians treat efficacy as class-wide. LLY's OMVOH has limited direct PsA exposure, so the practical implication is lower rather than a clean negative.

Immediate equity impact should be muted given JNJ's diversification and Phase 4, company-sponsored design. The 1-3 month catalyst is congress disclosure of absolute BASDAI/ASDAS-CRP and MRI deltas, placebo-adjusted safety, and consistency across skin/peripheral-joint endpoints; strong data can enable promotional and access momentum before any formal label action. The 6-18 month upside requires observable new-start share and incremental PsA sales, not merely a differentiated narrative.

Contrarian view: the headline may be less commercially decisive than it appears because no standardized axial-PsA definition limits clean patient identification, while MRI screening may select an enriched, more treatment-responsive population than routine practice. Thesis is falsified if detailed data show marginal clinical separation despite imaging improvement, if payer policies do not recognize axial involvement as a differentiating criterion, or if JNJ fails to raise TREMFYA growth commentary at subsequent earnings.

Key Decisions for Investors

• Maintain or add a modest JNJ overweight only on post-readout weakness; treat this as franchise-duration optionality rather than a near-term EPS catalyst. Reassess after detailed congress data and the next earnings call; exit incremental exposure if management does not identify PsA demand/share acceleration or if effect sizes are clinically marginal.
• Watch, do not initiate, a JNJ/ABBV relative-value trade until absolute STAR efficacy and commercial-access implications are disclosed. A long JNJ / short ABBV pair is justified only if data demonstrate materially differentiated objective and clinical outcomes and JNJ signals payer leverage; otherwise the mechanism is class validation, which can support both.
• For ABBV, monitor quarterly SKYRIZI PsA commentary, rheumatology new-start trends, and formulary positioning over the next 2-4 quarters. Any loss of axial-PsA differentiation would be a modest multiple risk, but insufficient alone to short a diversified franchise.
• Set an event alert for the scientific-congress presentation: key decision variables are placebo-adjusted MRI change, ASDAS clinically meaningful response rates, discontinuations, and whether results support regulatory-label engagement. Missing numerical detail is the primary reason not to price a material revenue uplift today.